Johnson & Johnson $JNJ Stock: Coerente Capital Management Decreases Stake

Key Points

• Coerente Capital Management cut its Johnson & Johnson stake by 2.7% in the third quarter, selling 4,218 shares; it still held 152,245 shares worth about $40.3 million.
• J&J reported quarterly adjusted earnings of $2.59 per share, above the $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. The company guided to fiscal 2026 EPS of $11.05–$11.15.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $275.92. J&J also announced a quarterly dividend of $1.34 per share, equivalent to a 2.0% yield at the article’s cited share price.

Coerente Capital Management lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 152,245 shares of the company's stock after selling 4,218 shares during the period. Johnson & Johnson accounts for approximately 7.0% of Coerente Capital Management's holdings, making the stock its 3rd biggest position. Coerente Capital Management's holdings in Johnson & Johnson were worth $40,305,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Outlook Capital Management LLC bought a new stake in Johnson & Johnson during the second quarter worth about $28,000. Matrix Trust Co grew its holdings in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares during the period. Montgomery Financial Services LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $43,000. Hanseatic Management Services Inc. bought a new position in shares of Johnson & Johnson during the third quarter valued at approximately $52,000. Finally, Polaris Financial Partners purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $56,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on JNJ shares. HSBC boosted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. TD Cowen reaffirmed a "buy" rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Sanford C. Bernstein set a $270.00 price objective on Johnson & Johnson in a research note on Thursday, October 15th. Wells Fargo & Company boosted their target price on Johnson & Johnson from $275.00 to $287.00 and gave the stock an "overweight" rating in a report on Friday, October 16th. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $282.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $266.10 on Wednesday. The firm's 50-day moving average price is $265.60 and its 200-day moving average price is $247.46. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a market cap of $640.59 billion, a PE ratio of 40.32, a PEG ratio of 2.67 and a beta of 0.22. Johnson & Johnson has a 52-week low of $185.12 and a 52-week high of $282.02.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm's quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is 81.21%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New real-world and observational analyses presented at TCT 2026 linked Impella-supported high-risk coronary procedures with lower mortality than prior study benchmarks; one report also cited a 94% procedural success rate. The findings could bolster the case for the heart-pump business, though further evidence, including the ongoing PROTECT IV trial, remains important. Article: Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Neutral Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors, but its alert provides no details about the claims or any legal action. The announcement alone does not establish wrongdoing or the likely financial impact. Article: Pomerantz Law Firm investigates claims on behalf of investors of Johnson & Johnson
• Negative Sentiment: The investor investigation is a potential source of uncertainty and could weigh on sentiment if it develops into substantive litigation or reveals material allegations. Article: Pomerantz Law Firm investigates claims on behalf of investors of Johnson & Johnson

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 64,515 shares of company stock worth $17,271,766. Insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.